Aditum Bio is a venture capital firm that focuses on acquiring and developing biotechnology assets that will benefit patients. The firm allows an alternative outlet for these discoveries as they advance into the clinic. It acquire these assets from biotechnology and pharma companies and develop them through Phase II utilizing TrialSpark as the innovative clinical research engine.